Skip to main content

Table 4 Evaluation of frequent side effect before/during/after ART and at timepoint of evaluation in 43 patients from 46 adjuvant radiotherapies

From: Toxicity and quality of life after choline-PET/CT directed salvage lymph node dissection and adjuvant radiotherapy in nodal recurrent prostate cancer

Variables Value CTCAE3-classification
Constipation   
Before ART 4/46 (8.7%) 4/4 (100%) grade 1
During ART 6/46 (13.0%) 6/6 (100%) grade 1
After ART1 6/46 (13.0%) 6/6 (100%) grade 1
Latest follow up2 5/37 (13.5%) 5/5 (100%) grade 1
Diarrhea   
Before ART 4/46 (8.7%) 4/4 (100%) grade 1
During ART 20/46 (43.5%) 15/20 (75.0%) grade 1/5/20 (25.0%) grade 2
After ART1 11/46 (23.9%) 11/11 (100%) grade 1
Latest follow up2 4/37 (10.8%) 4/4 (100%) grade 1
Rectal bleeding   
Before ART 3/46 (6.5%) 3/3 (100%) grade 1
During ART 2/46 (4.3%) 2/2 (100%) grade 1
After ART1 2/46 (4.3%) 2/2 (100%) grade 1
Latest follow up2 1/37 (2.7%) 1/1 (100%) grade 1
Nausea/Vomiting   
Before ART 0/46 (0.0%) -
During ART 4/46 (8.7%) 4/4 (100%) grade 1
After ART1 0/46 (0.0%) -
Latest follow up2 0/37 (0.0%) -
Haematuria   
Before ART 2/46 (4.3%) 2/2 (100%) grade 1
During ART 6/46 (13.0%) 6/6 (100%) grade 1
After ART1 4/46 (8.7%) 4/4 (100%) grade 1
Latest follow up2 1/37 (2.7%) 1/1 (100%) grade 1
Urinary incontinence   
Before ART 14/46 (30.4%) 12/14 (85.7%) grade 1/2/14 (14.3%) grade 2
During ART 17/46 (36.9%) 8/17 (47.1%) grade 1/9/17 (52.9%) grade 2
After ART1 16/46 (34.7%) 9/16 (56.3%) grade 1/7/16 (43.7%) grade 2
Latest follow up2 14/37 (37.8%) 10/14 (71.4%) grade 1/4/14 (28.6%) grade 2
Dysuria (urgency, feeling of obstruction, pain)   
Before ART 4/46 (8.7%) 4/4 (100%) grade 1
During ART 7/46 (15.2%) 7/7 (100%) grade 1
After ART1 5/46 (10.9%) 5/5 (100%) grade 1
Latest follow up2 4/37 (10.8%) 4/4 (100%) grade 1
Skin Erythema in radiated region   
Before ART 0/46 (0.0.%) -
During ART 13/46 (28.3%) 13/13 (100%) grade 1
After ART1 9/46 (19.6%) 6/9 (66.7%) grade 1/3/9 (33.3%) grade 2
Latest follow up2 1/37 (2.7%) 1/1 (100%) grade 1
Skin hyperpigmentation in radiated region   
Before ART 0/46 (0.0.%) -
During ART 0/46 (0.0.%) -
After ART1 6/46 (13.0%) 6/6 (100%) grad 1
Latest follow up2 3/37 (8.1%) 3/3 (100%) grade 1
Lymphedema extremity   
Before ART 5/46 (10.9%) 5/5 (100%) grade 1
During ART 6/46 (13.0%) 6/6 (100%) grade 1
After ART1 6/46 (13.0%) 6/6 (100%) grade 1
Latest follow up2 5/37 (13.5%) 5/5 (100%) grade 1
Lymphocele   
Before ART 2/46 (4.3%) 2/2 (100%) grade 1
During ART 3/46 (6.5%) 2/3 (66.7%) grade1/1/3 (33.3%) grade 2
After ART1 2/46 (4.3%) 2/2 (100%) grade 1
Latest follow up2 0/37 (0.0.%) -
Paresthesia   
Before ART 4/46 (8.7%) 4/4 (100%) grade 1
During ART 5/46 (10.9%) 5/5 (100%) grade 1
After ART1 5/46 (10.9%) 5/5 (100%) grade 1
Latest follow up2 5/37 (13.5%) 5/5 (100%) grade 1
Fatigue/exhaustion   
Before ART 10/46 (21.7%) 10/10 (100%)
During ART 17/46 (37.0%) 17/17 (100%)
After ART1 16/46 (34.8%) 16/16 (100%)
Latest follow up2 9/37 (24.3%) 9/9 (100%)
Thrombosis   
Before ART 0/46 (0.0.%) -
During ART 0/46 (0.0.%) -
After ART1 0/46 (0.0.%) -
Latest follow up2 0/37 (0.0.%) -
Embolism   
Before ART 0/46 (0.0.%) -
During ART 0/46 (0.0.%) -
After ART1 0/46 (0.0.%) -
Latest follow up2 0/37 (0.0.%) -
  1. ART = adjuvant radiotherapy.
  2. 1Mean 2.3 (SD: 1.2) months after end of radiotherapy.
  3. 2Mean 3.2 (SD: 2.8) years after end of radiotherapy.
  4. 3Common Terminology Criteria for Adverse Events Version 4.0.